Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.59
HZNP's Cash to Debt is ranked lower than
70% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. HZNP: 0.59 )
Ranked among companies with meaningful Cash to Debt only.
HZNP' s 10-Year Cash to Debt Range
Min: 0.07  Med: 1.12 Max: N/A
Current: 0.59
Equity to Asset 0.43
HZNP's Equity to Asset is ranked lower than
77% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. HZNP: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
HZNP' s 10-Year Equity to Asset Range
Min: -0.77  Med: 0.48 Max: 0.7
Current: 0.43
-0.77
0.7
F-Score: 3
Z-Score: 1.50
M-Score: -0.07
WACC vs ROIC
11.43%
6.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -6.75
HZNP's Operating margin (%) is ranked lower than
78% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. HZNP: -6.75 )
Ranked among companies with meaningful Operating margin (%) only.
HZNP' s 10-Year Operating margin (%) Range
Min: -1841.5  Med: -418.56 Max: -2.86
Current: -6.75
-1841.5
-2.86
Net-margin (%) -3.73
HZNP's Net-margin (%) is ranked lower than
76% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. HZNP: -3.73 )
Ranked among companies with meaningful Net-margin (%) only.
HZNP' s 10-Year Net-margin (%) Range
Min: -1635.12  Med: -465.90 Max: -88.77
Current: -3.73
-1635.12
-88.77
ROE (%) -2.84
HZNP's ROE (%) is ranked lower than
72% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. HZNP: -2.84 )
Ranked among companies with meaningful ROE (%) only.
HZNP' s 10-Year ROE (%) Range
Min: -523.78  Med: -115.60 Max: -57.66
Current: -2.84
-523.78
-57.66
ROA (%) -1.23
HZNP's ROA (%) is ranked lower than
70% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. HZNP: -1.23 )
Ranked among companies with meaningful ROA (%) only.
HZNP' s 10-Year ROA (%) Range
Min: -176.97  Med: -63.12 Max: -31.86
Current: -1.23
-176.97
-31.86
ROC (Joel Greenblatt) (%) -297.39
HZNP's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. HZNP: -297.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HZNP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4895.85  Med: -2664.68 Max: -154.09
Current: -297.39
-4895.85
-154.09
Revenue Growth (3Y)(%) 66.40
HZNP's Revenue Growth (3Y)(%) is ranked higher than
97% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. HZNP: 66.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HZNP' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -7.30 Max: 66.4
Current: 66.4
0
66.4
EPS Growth (3Y)(%) -36.90
HZNP's EPS Growth (3Y)(%) is ranked lower than
88% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. HZNP: -36.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HZNP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -26.00 Max: -36.9
Current: -36.9
» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

HZNP Guru Trades in Q4 2014

Steven Cohen 2,614,700 sh (+179.83%)
Joel Greenblatt 107,898 sh (+33.48%)
Paul Tudor Jones 274,577 sh (-6.86%)
» More
Q1 2015

HZNP Guru Trades in Q1 2015

Jim Simons 359,430 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones 45,508 sh (-83.43%)
Steven Cohen 233,900 sh (-91.05%)
» More
Q2 2015

HZNP Guru Trades in Q2 2015

RS Investment Management 964,160 sh (New)
RS Investment Management 964,160 sh (New)
Steve Mandel 3,204,972 sh (New)
Jim Simons 1,216,800 sh (+238.54%)
Paul Tudor Jones 137,400 sh (+201.92%)
Steven Cohen 325,000 sh (+38.95%)
» More
2015

HZNP Guru Trades in 2015

Steve Mandel 8,353,668 sh (+160.65%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Horizon Pharma PLC

Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma
Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (NASDAQ:HZNP), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
Forward P/E 11.56
HZNP's Forward P/E is ranked higher than
88% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. HZNP: 11.56 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.85
HZNP's P/B is ranked lower than
56% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. HZNP: 3.85 )
Ranked among companies with meaningful P/B only.
HZNP' s 10-Year P/B Range
Min: 0.8  Med: 2.36 Max: 14.89
Current: 3.85
0.8
14.89
P/S 7.94
HZNP's P/S is ranked lower than
76% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. HZNP: 7.94 )
Ranked among companies with meaningful P/S only.
HZNP' s 10-Year P/S Range
Min: 1.47  Med: 4.71 Max: 19.46
Current: 7.94
1.47
19.46
Current Ratio 3.09
HZNP's Current Ratio is ranked higher than
63% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. HZNP: 3.09 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s 10-Year Current Ratio Range
Min: 0.16  Med: 1.89 Max: 4.39
Current: 3.09
0.16
4.39
Quick Ratio 3.02
HZNP's Quick Ratio is ranked higher than
70% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. HZNP: 3.02 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s 10-Year Quick Ratio Range
Min: 0.16  Med: 1.74 Max: 4.27
Current: 3.02
0.16
4.27
Days Inventory 44.65
HZNP's Days Inventory is ranked higher than
84% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.66 vs. HZNP: 44.65 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s 10-Year Days Inventory Range
Min: 13.1  Med: 59.25 Max: 184.95
Current: 44.65
13.1
184.95
Days Sales Outstanding 143.56
HZNP's Days Sales Outstanding is ranked lower than
85% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. HZNP: 143.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s 10-Year Days Sales Outstanding Range
Min: 67.08  Med: 88.33 Max: 124.99
Current: 143.56
67.08
124.99

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 7.66
HZNP's Price/Projected FCF is ranked lower than
81% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. HZNP: 7.66 )
Ranked among companies with meaningful Price/Projected FCF only.
HZNP' s 10-Year Price/Projected FCF Range
Min: 8.73  Med: 22.25 Max: 94.46
Current: 7.66
8.73
94.46
Price/Median PS Value 1.72
HZNP's Price/Median PS Value is ranked lower than
68% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. HZNP: 1.72 )
Ranked among companies with meaningful Price/Median PS Value only.
HZNP' s 10-Year Price/Median PS Value Range
Min: 0.37  Med: 1.05 Max: 3.69
Current: 1.72
0.37
3.69
Earnings Yield (Greenblatt) (%) -0.61
HZNP's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. HZNP: -0.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HZNP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.1  Med: 0.00 Max: 0
Current: -0.61
-1.1
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 692 867 960
EPS($) 1.38 2.65 5.03
EPS without NRI($) 1.38 2.65 5.03

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice o Aug 27 2015 
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depo Aug 19 2015 
Horizon Pharma plc Sends Letter to Depomed, Inc Board of Directors Aug 13 2015 
Horizon Pharma plc Names George Hampton Executive Vice President, Global Orphan Business Unit and In Aug 07 2015 
Horizon Pharma plc Commences Process to Request a Special Meeting of Depomed, Inc. Shareholders Aug 03 2015 
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice o Jul 31 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
Horizon Pharma plc Announces Collaboration With Fox Chase Cancer Center to Study ACTIMMUNE(R) (inter Jul 27 2015 
Horizon Pharma plc Increases Offer for Depomed, Inc. to $33.00 per Share Jul 21 2015 

More From Other Websites
Wannabe buyer appeals to shareholders in contentious East Bay takeover Aug 28 2015
NRI.TO: Update on Second Quarter 2015 Financials Aug 27 2015
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice... Aug 27 2015
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice... Aug 27 2015
Call buyers come back to Horizon Aug 26 2015
Horizon Pharma's failed Depomed buyout Aug 20 2015
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice... Aug 20 2015
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice... Aug 20 2015
Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for... Aug 20 2015
Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc Aug 20 2015
Depomed rejects Horizon Pharma's offer for the third time Aug 19 2015
Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc Aug 19 2015
Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for... Aug 19 2015
Horizon Pharma gets vote of confidence Aug 18 2015
Horizon Pharma’s Specialty Business Unit in 2Q15 Aug 17 2015
Horizon Pharma Appears to Be on an Acquisition Spree Aug 17 2015
HORIZON PHARMA PLC Financials Aug 15 2015
Horizon Pharma’s Primary Care Business Unit in 2Q15 Aug 15 2015
Horizon Pharma Remains Affected by the Strong Dollar in 2Q15 Aug 14 2015
5 Under-the-Radar Growth Stocks to Buy Now Aug 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK